Diabetes
2021 marks the centenary of the discovery of insulin. Since that landmark discovery, huge advances have taken place in our understanding of the pathogenesis of type 1 diabetes and type 2 diabetes, as well as improvements in the treatment of patients with diabetes. This Milestone timeline highlights some of the key advances that have occurred in diabetes research over the past 100 years — from the development of synthetic insulin to new drug classes and technologies for the management of diabetes.
This Milestone is editorially independent, produced with financial support from a third party. About this content.
Nature Portfolio is pleased to acknowledge financial support from AstraZeneca, Medtronic Diabetes and Novo Nordisk A/S in producing this Milestone. The sponsors retain sole responsibility for the following messages.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
Founded in 1923, Novo Nordisk is a leading global healthcare company headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, cardiovascular disorders, and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease.
Standing on the shoulders of the discovery of insulin 100 years ago, we continue to lead the development of advanced insulin analogues and convenient delivery systems. We have pioneered innovation within GLP-1 and recently introduced the first-ever GLP-1 analogue in a tablet, the by far largest peptide for oral administration available to date.
Learn more about us and our broad pipeline at novonordisk.com. We also welcome you at LinkedIn, Facebook, Twitter (@novonordisk), Instagram (@novonordisk), and YouTube - and of course around the globe in the 169 countries where we market our products.
